keyword
https://read.qxmd.com/read/36966521/safety-and-performance-of-intravenous-pumps-and-syringe-drivers-in-hyperbaric-environments
#1
REVIEW
Aisha Al Balushi, David Smart
INTRODUCTION: Critically ill patients require continuation of their care when receiving hyperbaric oxygen treatment. This care may be facilitated via portable electrically powered devices such as intravenous (IV) infusion pumps and syringe drivers, which may create risks in the absence of a comprehensive safety evaluation. We reviewed published safety data for IV infusion pumps and powered syringe drivers in hyperbaric environments and compared the evaluation processes to key requirements documented in safety standards and guidelines...
March 31, 2023: Diving and Hyperbaric Medicine: the Journal of the South Pacific Underwater Medicine Society
https://read.qxmd.com/read/36966520/the-risk-of-decompression-illness-in-breath-hold-divers-a-systematic-review
#2
REVIEW
S Lesley Blogg, Frauke Tillmans, Peter Lindholm
INTRODUCTION: Breath-hold (BH) diving has known risks, for example drowning, pulmonary oedema of immersion and barotrauma. There is also the risk of decompression illness (DCI) from decompression sickness (DCS) and/or arterial gas embolism (AGE). The first report on DCS in repetitive freediving was published in 1958 and from then there have been multiple case reports and a few studies but no prior systematic review or meta-analysis. METHODS: We undertook a systematic literature review to identify articles available from PubMed and Google Scholar concerning breath-hold diving and DCI up to August 2021...
March 31, 2023: Diving and Hyperbaric Medicine: the Journal of the South Pacific Underwater Medicine Society
https://read.qxmd.com/read/36966517/a-review-of-149-divers-alert-network-emergency-call-records-involving-diving-minors
#3
JOURNAL ARTICLE
Elizabeth T Helfrich, Camilo M Saraiva, James M Chimiak, Matias Chimiak
INTRODUCTION: Minors have been scuba diving for decades, and while the initial concerns about potential long-term complications related to bone development appear to be unfounded, the incidence of scuba diving injuries among them has been poorly studied. METHODS: We reviewed 10,159 cases recorded in the DAN Medical Services call centre database from 2014 through 2016 and identified 149 cases of injured divers younger than 18 years. Records were analysed for case categorisation on the most common dive injuries...
March 31, 2023: Diving and Hyperbaric Medicine: the Journal of the South Pacific Underwater Medicine Society
https://read.qxmd.com/read/36966516/effects-of-external-bleeding-and-hyperbaric-oxygen-treatment-on-tamai-zone-1-replantation
#4
JOURNAL ARTICLE
Yavuz Tuluy, Alper Aksoy, Emin Sir
INTRODUCTION: Tamai zone 1 replantation poses a challenge due to the very small size of the vascular structures; often there is no vein for anastomosis. Replantation may have to be done with only an arterial anastomosis. In our study, we aimed to evaluate the success of replantation by combining external bleeding and hyperbaric oxygen treatment (HBOT) in Tamai zone 1 replantation. METHODS: Between January 2017 and October 2021, 17 finger replantation patients who underwent artery-only anastomosis due to Tamai zone 1 amputation received 20 sessions of HBOT with external bleeding after the 24th postoperative hour...
March 31, 2023: Diving and Hyperbaric Medicine: the Journal of the South Pacific Underwater Medicine Society
https://read.qxmd.com/read/36966503/challenges-in-the-management-of-relapsed-germ-cell-tumors
#5
JOURNAL ARTICLE
Tareq Salous, Nabil Adra
PURPOSE OF REVIEW: Despite the remarkable advances in the treatment of germ cell tumors (GCTs), a significant number of patients relapse after first line treatment. This review aims to highlight the challenges in management of relapsed GCT, discuss treatment options, and review novel therapeutics in development. RECENT FINDINGS: Patients with relapsed disease after first line cisplatin-based chemotherapy can still be cured and should be referred to centers with expertise in GCTs...
March 3, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966502/molecular-testing-of-dna-damage-response-pathways-in-prostate-cancer-patients
#6
JOURNAL ARTICLE
Lalit Patel, Colin C Pritchard
PURPOSE OF REVIEW: Personalizing prostate cancer therapy requires germline and tumor molecular tests that predict who will respond to specific treatments and who may not. The review covers molecular testing of DNA damage response pathways, the first biomarker-driven precision target with clinical utility for treatment selection in patients with castration resistant prostate cancer (CRPC). RECENT FINDINGS: Recurrent somatic and germline variants cause deficiency of the mismatch repair (MMR) or homologous recombination (HR) pathways in about a quarter of CRPC patients...
March 7, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966501/window-of-opportunity-clinical-trials-for-biomarker-discovery-in-head-and-neck-squamous-cell-carcinoma
#7
JOURNAL ARTICLE
Grégoire Marret, Edith Borcoman, Christophe Le Tourneau
PURPOSE OF REVIEW: We review the window-of-opportunity clinical trials that have been reported in head and neck squamous cell carcinoma (HNSCC), and discuss their challenges. RECENT FINDINGS: Limited treatment options exist in HNSCC. Cetuximab, an mAb targeting epidermal growth factor receptor, and the PD-1 inhibitors nivolumab and pembrolizumab, are the only drugs that improved overall survival in the recurrent and/or metastatic setting. Both cetuximab and nivolumab improve overall survival by less than 3 months, potentially because of the lack of predictive biomarkers...
March 15, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966500/how-to-prevent-human-papillomavirus-related-oropharyngeal-cancer
#8
JOURNAL ARTICLE
Angelica Ferrando-Díez, Miguel Angel Pavón, Beatriz Cirauqui, Laia Alemany, Ricard Mesía
PURPOSE OF REVIEW: Human papillomavirus (HPV) is responsible of the increasing incidence rates of oropharyngeal squamous cell carcinoma (OPSCC) in high-income countries. This significant epidemiological change requires several and diverse prevention strategies. RECENT FINDINGS: The cervical cancer prevention model is the paradigm of HPV-related cancer, and its success provides encouragement for the development of similar methods to prevent HPV-related OPSCC. However, there are some limitations that hinder its application in this disease...
March 21, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966499/liquid-biopsy-in-head-neck-cancer-ready-for-clinical-routine-diagnostics
#9
JOURNAL ARTICLE
Ingeborg Tinhofer, Stephanie Staudte, Stephen George
PURPOSE OF REVIEW: The bodily fluids of patients with solid cancers representing a minimally-invasive source of clinically exploitable biomarkers have attracted an increasing amount of attention in recent years. In patients with head and neck squamous cell carcinoma (HNSCC), cell-free tumour DNA (ctDNA) belongs to the most promising liquid biomarkers for monitoring disease burden and identifying patients at high risk of recurrence. In this review, we highlight recent studies, evaluating the analytical validity and clinical utility of ctDNA as a dynamic biomarker in HNSCC, especially as it relates to risk stratification and contrasting human papilloma virus (HPV+ and HPV-) and carcinomas...
March 20, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966498/targeting-harvey-rat-sarcoma-viral-oncogene-homolog-in-head-and-neck-cancer-how-to-move-forward
#10
JOURNAL ARTICLE
Hédi Ben Yahia, François M Petit, Esma Saada-Bouzid
PURPOSE OF REVIEW: Despite recent advances, treatment personalization remains an issue for recurrent metastatic head and neck squamous cell carcinoma (RM HNSCC) patients. After human papilloma virus (HPV) and programmed death ligand 1 (PDL1) expression, Harvey rat sarcoma viral oncogene homolog (HRAS) appears as an emerging target in this field. In this review, we summarize the features of HRAS-mutated HNSCC and its targeting by farnesyl transferase inhibitors. RECENT FINDINGS: HRAS mutations define a small subgroup of RM HNSCC patients with a poor prognosis and often refractory to the standard treatments...
March 20, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966497/evolving-systemic-management-of-urothelial-cancers
#11
JOURNAL ARTICLE
Wei Shen Tan, Mae-Yen Tan, Omar Alhalabi, Matthew T Campbell, Ashish M Kamat, Jianjun Gao
PURPOSE OF REVIEW: Bladder cancer is the 12th most common cancer worldwide. Historically, the systemic management of urothelial carcinoma has been confined to platinum-based chemotherapy. In this review, we discuss the evolving landscape of systemic treatment for urothelial carcinoma. RECENT FINDINGS: Since 2016, when the Food and Drug Administration approved the first immune checkpoint inhibitor (CPI), programmed cell death 1 and programmed cell death ligand 1 inhibitors have been evaluated in the nonmuscle invasive bladder cancer, localized muscle invasive bladder cancer as well as advanced/metastatic bladder cancer settings...
March 15, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966496/hybrid-magnetic-resonance-and-pet-imaging-for-prostate-cancer-recurrence
#12
JOURNAL ARTICLE
Nikita Rednam, Vikas Kundra
PURPOSE OF REVIEW: Recurrence post definitive local therapy by prostatectomy or radiation therapy is often detected via rise in serum prostate-specific antigen (PSA) levels; however, PSA rise does not localize the disease. Distinguishing local versus distant recurrence guides whether to choose subsequent local versus systemic therapy. The purpose of this article is to review imaging for prostate cancer recurrence post local therapy. RECENT FINDINGS: Among imaging modalities, multiparametric MRI (mpMRI) is commonly used to assess for local recurrence...
March 6, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966495/chemotherapy-postimmunotherapy-for-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma
#13
JOURNAL ARTICLE
Agnes Ducoulombier, Joel Guigay, Marie-Christine Etienne-Grimaldi, Esma Saada-Bouzid
PURPOSE OF THE REVIEW: Clinical data on salvage chemotherapy used after checkpoints inhibitors in oncology are reviewed, with a special focus on recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). RECENT FINDINGS: Converging evidence is emerging about high response and/or disease control rates associated with salvage chemotherapy after immunotherapy failure in advanced solid tumours. This phenomenon is mainly reported in retrospective studies for "hot tumours" such as R/M HNSCC, melanoma, lung, urothelial or gastric cancers, but also in haematological malignancies...
March 15, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966494/treatments-and-challenges-in-advanced-prostate-cancer
#14
JOURNAL ARTICLE
Theodore Gourdin, Arash Velayati
PURPOSE OF REVIEW: This review is designed to highlight recent research examining treatment progress in advanced prostate cancer while identifying ongoing challenges to clinical outcomes. RECENT FINDINGS: Recent randomized trials suggest an overall survival advantage to treating some men with newly identified metastatic prostate cancer with a "triplet" of androgen deprivation therapy, docetaxel, and an androgen receptor axis-targeted agent. Questions remain about which men are best served by these combinations...
March 20, 2023: Current Opinion in Oncology
https://read.qxmd.com/read/36966492/iloprost-for-the-treatment-of-frostbite-a-scoping-review
#15
JOURNAL ARTICLE
Josianne Gauthier, Dunavan Morris-Janzen, Alexander Poole
We performed a scoping review to identify the extent of the literature describing the use of iloprost in the treatment of frostbite. Iloprost is a stable synthetic analog of prostaglandin I2 . As a potent inhibitor of platelet aggregation and vasodilator, it has been used to address the post-rewarming reperfusion injury in frostbite. The search using iloprost and frostbite as key words and MeSH terms yielded 200 articles. We included in our review the literature examining iloprost for the treatment of frostbite in humans in the form of primary research, conference proceedings and abstracts...
December 2023: International Journal of Circumpolar Health
https://read.qxmd.com/read/36966477/systemic-immune-inflammation-index-predicts-prognosis-and-responsiveness-to-immunotherapy-in-cancer-patients-a-systematic-review-and-meta%C3%A2-analysis
#16
JOURNAL ARTICLE
Junyan Kou, Jing Huang, Jun Li, Zhen Wu, Liwei Ni
The systemic immune-inflammation index (SII) is a significant prognostic factor in some cancer types. However, the prognostic role of SII in cancer patients with immunotherapy remains uncertain. We aimed to evaluate the relationship between pretreatment SII and clinical survival outcomes for advanced-stage cancer patients treated with immune checkpoint inhibitors (ICIs). A comprehensive literature search was performed to identify eligible studies concerning the association between pretreatment SII and survival outcomes in advanced cancer patients treated with ICIs...
March 26, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/36966473/mediating-role-of-psychological-resilience-in-the-relationship-between-self-efficacy-and-professional-identity-among-nurses
#17
JOURNAL ARTICLE
Ruonan Yi, Zhenhong Zhou, Wenyuan Ma, Chunling Yang, Fengling Wang, Jianghua Wu
To explore the mediating role of resilience in the relationship between general self-efficacy and professional identity of nurses during the COVID-19 pandemic. A cross-sectional design was employed. A total of 982 nurses from four Grade III, class A hospitals in Shandong Province were investigated using general information questionnaire, nurses' professional identity rating scale, general self-efficacy scale (GSES), and Connor-Davidson flexibility scale (CD-RISC). SPSS22.0 and Amos21.0 were used for data analysis and structural equation modeling...
March 26, 2023: Biotechnology & Genetic Engineering Reviews
https://read.qxmd.com/read/36966454/the-therapeutic-potential-of-immunotherapy-in-the-treatment-of-breast-cancer-rational-strategies-and-recent-progress
#18
REVIEW
Hossein Javid, Fatemeh Attarian, Toktam Saadatmand, Nastaran Rezagholinejad, Ali Mehri, Hamed Amiri, Mehdi Karimi-Shahri
The second leading cause of cancer death in women worldwide is breast cancer (BC), and despite significant advances in BC therapies, a significant proportion of patients develop metastasis and disease recurrence. Currently used treatments, like radiotherapy, chemotherapy, and hormone replacement therapy, result in poor responses and high recurrence rates. Alternative therapies are therefore needed for this type of cancer. Cancer patients may benefit from immunotherapy, a novel treatment strategy in cancer treatment...
March 26, 2023: Journal of Cellular Biochemistry
https://read.qxmd.com/read/36966453/a-narrative-review-of-acthar-gel-for-the-treatment-of-myositis
#19
REVIEW
Tanya Chandra, Rohit Aggarwal
Idiopathic inflammatory myopathies (IIMs) are autoimmune disorders characterized by symmetric proximal muscle weakness and chronic inflammation, with an increased risk of morbidity and mortality. The current standard of care includes traditional immunosuppressive pharmacotherapies; however, some patients cannot tolerate or do not adequately respond to these therapies, highlighting the need for alternative treatments for refractory disease. Acthar® Gel (repository corticotropin injection) is a naturally sourced mixture of adrenocorticotropic hormone analogs and other pituitary peptides that has been approved by the US Food and Drug Administration since 1952 for use in patients with two subgroups of IIMs, dermatomyositis (DM) and polymyositis (PM)...
March 26, 2023: Rheumatology and Therapy
https://read.qxmd.com/read/36966443/study-on-different-sequences-of-painless-gastroenteroscopy-in-patients-with-difficult-airway
#20
JOURNAL ARTICLE
Huirui Sun, Linghua Zhang, Zhixian Liu, Yanping Zhang, Jieping Li, Kunfang Pang
The selection of different examination sequences of painless gastroscopy in patients with difficult airway risk was explored in this study. A total of 45 patients undergoing painless gastroscopy with Mallampati airway score of III-IV were randomly assigned into two groups (A group and B group) according to the sequence of colonoscopy and gastroscopy. Group A was first examined by gastroscopy after anesthesia, and then by colonoscopy. Group B was examined in the opposite order, first by colonoscopy, and then by gastroscopy...
March 26, 2023: Biotechnology & Genetic Engineering Reviews
keyword
keyword
2088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.